| Patent application number | Description | Published |
|---|
| 20080318899 | Pyridazine Compounds, Compositions and Methods - The invention relates to novel chemical compounds and methods of making and using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications. | 12-25-2008 |
| 20090029985 | PYRIDAZINE COMPOUNDS AND METHODS - The invention relates to novel chemical compounds, compositions and methods of making and using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications. | 01-29-2009 |
| 20090221613 | Use of Adenine-Derived Compounds for the Treatment of Lupus - The invention relates to the use of adenine-derived compounds substituted in the 2- and 9-positions and, optionally, in the N(6)-position of the adenine, for the manufacture of a medicament for use in the treatment of systemic lupus erythematosus (SLE). The compounds can also be used in combination with a second compound used in the treatment of SLE. | 09-03-2009 |
| 20090270495 | Inhibitors of Phosphodiesterase Types 1 To 5 Based on Dioclein, Floranol, and Analogs Thereof - We disclose substances and a process of developing such substances as potent and selective inhibitors of isoforms of phosphodiesterases of types 1 to 5 (PDE1, PDE2, PDE3, PDE4, PDE5) based on two flavonoids: dioclein, floranol and natural or synthetic analogs thereof. They may be associated with cyclodextrins in inclusion complexes or using a biodegradable or non-biodegradable polymer, such as PLGA, PLA, PGA or mixtures thereof in controlled release devices. Their respective pharmaceutical compositions as well as pharmaceutical and pharmacologically acceptable excipients may be used for the study and treatment of cardiovascular diseases and associated products. | 10-29-2009 |
